Amgen 說研究不可重複，實際上是說其發現不可用來開發藥物

http://www.nature.com/nature/journal/v483/n7391/full/483531a.html

http://www.nature.com/nature/journal/v485/n7396/full/485041e.html

The term 'non-reproduced' was assigned on the basis of findings not being sufficiently robust to drive a drug-development programme.

Table 1: Reproducibility of research findings
Preclinical research generates many secondary publications, even when results cannot be reproduced.
From
Drug development: Raise standards for preclinical cancer research
C. Glenn Begley & Lee M. Ellis
Nature 483, 531–533 (29 March 2012) doi:10.1038/483531a
back to article
Table 1: Reproducibility of research findings
Preclinical research generates many secondary publications, even when results cannot be reproduced.
Journal impact factor Number of articles Mean number of citations of non-reproduced articles* Mean number of citations of reproduced articles


>20 21 248 (range 3–800) 231 (range 82–519)
5–19 32 169 (range 6–1,909) 13 (range 3–24)

Results from ten-year retrospective analysis of experiments performed prospectively. The term 'non-reproduced' was assigned on the basis of findings not being sufficiently robust to drive a drug-development programme.

所有跟帖： 

• 不能用來做藥有多種原因，比如體外或動物實驗不能在臨床重複，或者副作用太大。這裏的原因是實驗結果不robust，不能反複驗證。 -viewfinder- ♀ (159 bytes) () 10/02/2014 postreply 08:04:29

• Amgen是用發表文章完全相同的實驗方法，並且跟原作者聯係，有的實驗材料也是原作者提供的，但還不能可靠地重複實驗結果。 -viewfinder- ♀ (195 bytes) () 10/02/2014 postreply 08:08:48

• 可參考上麵分析方法技術轉移的例子。 -26484915- ♂ (0 bytes) () 10/02/2014 postreply 08:17:21

• 所以說你覺得不能重複是驗證者的問題。不排除這種可能。不好驗證，也就難以把關，需要發文章的人自覺。我是不會無條件相信的。 -viewfinder- ♀ (0 bytes) () 10/02/2014 postreply 10:58:51

• 是一個因素。但主要是標準不同。初期研究結果往往比較粗糙。 -26484915- ♂ (0 bytes) () 10/02/2014 postreply 11:27:45

• 藥物研發有一步就叫做 target validation. -26484915- ♂ (0 bytes) () 10/02/2014 postreply 08:16:24